Literature DB >> 1696595

The in vivo elimination of CD4+ T cells prevents the induction but not the expression of carrier-induced epitopic suppression.

C Leclerc1, M P Schutze, E Deriaud, G Przewlocki.   

Abstract

Injection of mice with an immunogenic dose of carrier (keyhole limpet hemocyanin (KLH)) followed by immunization with hapten-carrier conjugate (TNP-KLH) selectively suppresses anti-hapten antibody response. In this study, the cellular basis of this epitopic suppression and also of the suppression induced by a high dose of carrier were analyzed by in vivo depletion of CD4+ or CD8+ T cell subsets by using mAb. The mAb treatments were performed either at the time of carrier priming or at the time of hapten-carrier immunization. The elimination of CD8+ T cells has not modified the anti-carrier antibody response, whether this treatment was performed at the time of KLH-priming or during TNP-KLH immunization. Moreover, the in vivo treatment with the anti-CD8 mAb did not modify the carrier-induced epitopic suppression induced either by a low immunogenic dose of KLH or by a high dose of this Ag. The elimination of CD4+ T cells at the time of KLH immunization has prevented the induction of a memory response to KLH, clearly establishing that CD4+ T cells are essential in memory B cell development to T-dependent Ag. Moreover, this treatment has totally abrogated the epitopic suppression induced either by low or high dosages of KLH. In contrast, the in vivo elimination of CD4+ T cells after carrier immunization did not abolish the secondary anti-carrier antibody response and did not prevent the expression of epitopic suppression. These data indicate that primed CD4+ T cells are required neither for memory B cell expression nor for the expression of suppression. Finally, once induced, the suppression can be evidenced after in vivo depletion of both primed CD4+ and CD8+ T cells. These data support the view that epitopic suppression is induced through the expansion of carrier-specific B cells and resulted from intramolecular antigenic competition between hapten and carrier epitopes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696595

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.

Authors:  Ron Dagan; David Goldblatt; James R Maleckar; Mansour Yaïch; Juhani Eskola
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

2.  Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man.

Authors:  M R Downham; T R Auton; A Rosul; H L Sharp; L Sjöström; A Rushton; J P Richards; T G K Mant; S M Gardiner; T Bennett; J F Glover
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

3.  Bypass of carrier-induced epitope-specific suppression using a T-helper epitope.

Authors:  S Sad; K Rao; R Arora; G P Talwar; R Raghupathy
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

4.  Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines.

Authors:  C C Peeters; A M Tenbergen-Meekes; J T Poolman; M Beurret; B J Zegers; G T Rijkers
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

5.  A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.

Authors:  Xinle Cui; Zhouhong Cao; Goutam Sen; Gouri Chattopadhyay; Deborah H Fuller; James T Fuller; Dustin M Snapper; Andrew L Snow; James J Mond; Clifford M Snapper
Journal:  Vaccine       Date:  2013-05-09       Impact factor: 3.641

6.  Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants.

Authors:  R Dagan; J Eskola; C Leclerc; O Leroy
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

7.  A first or dominant immunization. I. Suppression of simultaneous cytolytic T cell responses to unrelated alloantigens.

Authors:  D A Rowley; R M Stach
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

Review 8.  Carbohydrate Conjugates in Vaccine Developments.

Authors:  Shuyao Lang; Xuefei Huang
Journal:  Front Chem       Date:  2020-04-15       Impact factor: 5.221

Review 9.  Factors contributing to the immunogenicity of meningococcal conjugate vaccines.

Authors:  Michael Bröker; Francesco Berti; Paolo Costantino
Journal:  Hum Vaccin Immunother       Date:  2016-03-02       Impact factor: 3.452

Review 10.  Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune Responses.

Authors:  Sharmeen Nishat; Peter R Andreana
Journal:  Vaccines (Basel)       Date:  2016-05-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.